Skip to content

Study · Animal study (in vivo) · guinea-pig and rat · 1981

1 result

[Correction of the T immunological system deficit in experimental and clinical tuberculosis].

Alexandrova AE, Vasiliev AV, Greimer MS, Zabolotnîh NV, Kniajeţkaia EJ, Kozlova NV, Talanova AG, Scerbakova NM

Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia1 Apr 1981

PMID6264576 (opens in a new tab)PepBankPUB-06264576
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In infected guinea-pigs and thymectomized rats, Timalin reduced tuberculosis severity, similarly to thymus grafts.

    In plain wordsIn guinea-pigs and rats with tuberculosis, Timalin reduced disease severity, similarly to thymus grafts.

    Peptide
    Thymalin
    Outcome
    DecreaseSeverity of tuberculous process
    Study

    guinea-pig and ratn: not reported in source

    M. tuberculosis infection in guinea-pigs and thymectomized rats
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated · subcutaneousAs given in this study (guinea-pig and rat).

    Source sentences

    Summary
    A similar effect is obtained by the subcutaneous injection of a thymus preparation called Timalin.
    2 context sentences
    Summary · context
    is accompanied by a considerable decrease in the severity of the tuberculous process.
    Summary · context
    to guinea-pigs infected with M. tuberculosis, or to white rats that had underwent thymectomy and had been infected

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.